

**UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
CURRICULUM VITAE**

FRANCISCO VEGA, MD, PhD

1. Date: January, 2017

I. PERSONAL

2. Current Academic Rank: Professor
3. Primary Department: Pathology (Hematopathology)
4. Secondary Joint Appointment: Clinical Medicine (Professor)
5. Citizenship: United States of America
6. Visa Type: N/A

II. HIGHER EDUCATION:

11. Institutional:

University Complutense of Madrid,
Doctor of Medicine and Surgery, June 1992
Madrid, Spain

University of Navarra
Doctor of Philosophy (Cell Biology), 1997
Pamplona, Spain

12. Non-Institutional:

Residency: Department of Anatomic Pathology, Clinical
University of Navarra, Pamplona, Spain
January 1994 – December 1997

Fellowship: Department of Hematopathology, Research
The University of Texas MD Anderson Cancer Center
December 1999 – August 2002

Fellowship: Department of Pathology, Research
Baylor College of Medicine
September 2002 – March 2003

Residency: Department of Anatomic Pathology, Clinical
Baylor College of Medicine

March 2003 – March 2005

Fellowship: Department of Hematopathology, Clinical
The University of Texas MD Anderson Cancer Center
July 2005 – June 2006

13. Certification, Licensure:

Florida Medical Board, June 2013 – January 2017
Texas Medical Board, October 2006 – November 2015
American Board of Hematopathology, September 2007
American Board of Anatomic Pathology, August 2005
License in Anatomic Pathology, Spain, December 1997
License in Medicine and Surgery, Spain, July 1992
Educational Commission for Foreign Medical Graduates, August 2002
Indiana Medical Board, 2005 – 2007 (inactive)

III. EXPERIENCE/SERVICE

14. Academic Appointments

University of Miami/Sylvester Comprehensive Cancer Center
Professor, Department of Clinical Medicine
July 2015 – Present

University of Miami/Sylvester Comprehensive Cancer Center
Professor, Hematopathology, Department of Pathology
September 2013 – Present

Member of the Sheila and David Fuente Graduate Program in Cancer Biology
University of Miami
February 2014-Present

The University of Texas MD Anderson Cancer Center
Associate Professor, Tenure, Department of Hematopathology, Pathology/Lab
Medicine
September 2011- August 2013

The University of Texas MD Anderson Cancer Center
Assistant Professor, Department of Hematopathology
July 2006 – September 2011

15. Hospital Appointments

Complejo Hospitalario de Orense (Spain)
Faculty, Department of Anatomic Pathology

January 1998 –November 1999

16. Non-Academic: None

17. Military: None

IV. PUBLICATIONS

18. Books and Monographs published:

1. Multiple book chapters for the forth series of the Tumors of the Lymph node and Spleen lymphoma; Atlas of Tumor Pathology of the AFIP (Armed Forces Institute of Pathology) Scheduled for 2016-2017.
2. Blieden C, Agarwal NK, **Vega F**. Microenvironment abnormalities and cytokine network deregulation in lymphoma genesis and progression. Future Science Group. UK, London, 35-50, 2015
3. **Vega F**. Lymphomas involving the lung and pleura. In: Annikka Weissferdt & Cesar A. Moran, editors. Diagnostic Pathology of Pleuropulmonary Neoplasia. Springer: New York, 319-347, 2013.
4. Leventaki V, **Vega F**. Molecular Diagnostics of Lymphoid Malignancies. In: Cheng, Zhang and Eble editors. Molecular Genetic Pathology. 2nd edition Springer. 887-928, 2013.
5. Cho-Vega JH, **Vega F**. Essentials in Cancer Cytogenetics. In: Garcia-Foncillas, J editor. Molecular Biology in cancer, an approach to new therapies. Barcelona: Prouse Science: Barcelona, 1-27, 2009.
6. **Vega F**, Jones D. Molecular Diagnostics of Lymphoid Malignancies. In: Essentials of Molecular/Genetic Pathology. Humana Press, 655-674, 2008.
7. **Vega F**, Toledo G. Alteraciones Anatomico-Patologicas de las Vias Aereas en el Asma bronquial. In: Asma Vision Actual. Aula Medica Ediciones, 33-54, 2001.
8. Idoate M, **Vega F**. Mecanismos Implicados en la Afectacion Cutanea por la Enfermedad de Injerto contra Huesped. In: Fisiopatologia de las Enfermedades Cutaneas II. Schering Plough, 281-303, 1999.
9. Cervera J, **Vega F**, Garcia-Tapia R. Estructura Histologica de las Cuerda Vocal. In: Diagnostico y Tratamiento de la Voz. Garsi, 48-53, 1996.
10. Cervera J, **Vega F**, Garcia-Tapia R. Lesiones Benignas de las Cuerdas Vocales. In: Diagnostico y Tratamiento de los Transtornos de la Voz. Garsi, 223-240, 1996.

11. **Vega F**, Panizo A, Pardo-Mindan FJ. Características Biológicas de los Tumores. In: Enfermería Oncológica. Ediciones Eunsa, 15-45, 1995.

Author of the following chapters for the Book Diagnostic Pathology Series Amirsys:
-Lymphomas and reactive diseases involving lymph nodes, spleen with extranodal lymphomas. In: LJ Medeiros editor. Amirsys publishing. Salt Lake City, Utah.

Syphilitic Lymphadenitis 2:54-55,
Inflammatory Pseudotumor Involving Lymph Node 3:2-7,
Diffuse Large B-cell Lymphoma, NOS, centroblastic 6:52-55,
Diffuse Large B-cell Lymphoma, NOS, Immunoblastic 6:56-61,
T-cell/Histiocyte Rich Large B-cell Lymphoma 6:62-65,
Plasmablastic Lymphoma 7:68-77,
Primary effusion lymphoma (PEL) and solid variant of PEL 7:78-83,
Primary Mediastinal (Thymic) Large B-cell Lymphoma 7:34-43,
Lymphomatoid Granulomatosis 7:86-95,
Intravascular Large B-cell Lymphoma 7:96-101,
B-cell Lymphomas, unclassifiable, with features intermediate between Diffuse Large B cell Lymphoma and Classical Hodgkin Lymphoma 8:8-17,
Anaplastic Large Cell Lymphoma, ALK+ 9:30-35,
Anaplastic Large Cell Lymphoma, ALK-, 9:36-39,
Classical Hodgkin Lymphoma in Spleen, 14:82-85
Hepatosplenic T-cell Lymphoma, 14:86-95.

-Author of additional chapters for the Diagnostic Pathology Series for the following books:

Neoplastic Dermatopathology. In: D. Cassarino editor. Amirsys publishing, 2013
Intravascular large B cell lymphoma involving the skin, I12:28-31.

Familial Cancer Syndromes. In: V. Nose editor. Amirsys publishing, 2014
Diffuse large B cell lymphoma, II-2:8-13.

Diagnostic Pathology Spleen. In A. Auerbach editor. Amirsys publishing, 2014
Hepatosplenic T-cell lymphoma, 3:208-215.

Manuals, Teaching Aids

Pardo-Mindan FJ, Sola I, Idoate M, de Alva E, Lozano MD, Panozo A, **Vega F**, Diaz L, Fernandez J. CD-ROM INTERPAT Interactive Teaching of Anatomic Pathology by Computer, 1999. Pamplona (Navarra, Spain).

19. Juried or Refereed Journal Articles or Exhibitions:

1. Chapman J, **Vega F**. Indolent ALK-Negative Anaplastic Large Cell Lymphoma, *DUSP22* Rearranged, with an Unusual Immunophenotype in an HIV Patient. *Histopathology*, 2017 (In press).
2. Villada G, **Vega F**. Clusters of paracortical plasmacytoid dendritic cells in lupus lymphadenitis. *Blood*, 2017 (In press)
3. Desai A, Joag MG, Lekakis L, Chapman JR, **Vega F**, Tibshirani R, Tse D, Markoe A, Lossos IS. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single institution cohort study. *Blood* 2016 (In press)
4. Gil VS, Bhagat G, Howell L, Zhang J, Kim CH, Stengel S, **Vega F**, Zelent A, Petrie K. Deregulated expression of HDAC9 in B-cells promotes development of lymphoproliferative disease and lymphoma. *Dis Model Mech*. 2016 (In press)
5. Cortizas E, Zahn A, Safavi S, Reed J, **Vega F**, Di Noia J, Verdun R. UNG protects B cells from AID-induced telomere loss. *J Exp Med* 2016 (In press)
6. Mackrides N, Campuzano-Zuluaga G, Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, Levy R, Verdun RE, Kunakalla K, Natkuman Y, Lossos IS, **Vega F**, Chapman J. EBV-positive follicular lymphoma. *Mod Path* 2016 (In press)
7. De la Fuente MI, Haggiani A, Moul A, Young RJ, Sidani C, Markoe A, **Vega F**, DeAngelis LM, Lossos IS. Marginal Zone Dural Lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami Experiences. *Leuk Lymph* 2016 (In press) PIMD 27649904
8. Alderuccio JP, Amarapurkar P, Chapman JR, **Vega F**, Lossos IS. Characteristics and outcomes of lymphoblastic lymphoma – the University of Miami experience. *Leuk Lymph* 2:1-4 2016. PIMD 27252116
9. Kozloski GA, Jiang X, Bhatt S, Ruiz J, **Vega F**, Shaknovich R, Melnick A, Lossos IS. MiR-181a negatively regulates NF- κ B signaling and affects activated B-cell like diffuse large B-cell lymphoma pathogenesis. *Blood* 127;2856-66; 2016. PMID: 26941399
10. Agarwal NK, Kim CH, Kunkalla K, Konno H, Tjendra Y, Kwon D, Blonska M, Kozloski GA, Moy VT, Verdun RE, Barber GN, Lossos IS, **Vega F**. Active IKK β Promotes the Stability of GLI1 Oncogene in Diffuse Large B-cell Lymphoma. *Blood* 127:605-615; 2016. PMID: 26603838
11. Yabe M, Medeiros LJ, Tang G, Wang S, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel K, Routnort M, Luthra R, Fanale M, Bueso-Ramos C, Jorgensen J, **Vega F**, Chen W, Hoehn D, Konoplev S, Milton D, Wistuba I, Li S, You J, Young K, Miranda R. Prognostic factors of Hepatosplenic T cell lymphoma. Clinicopathologic study of 28 cases. *Am J Surg Pathol* 40; 676-88; 2016 PMID:26872013

12. Campuzano-Zuluaga G, Deutsch Y, Salzberg M, Gomez A, Vargas F, Elias R, Kwon D, Goodman M, Ikpatt OF, Chapman JR, Watts J, **Vega F**, Swords R. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better? *Am J Hematol* 91:277-82; 2016. PMID:26663264
13. Campuzano-Zuluaga G, Ortiz D, Peng JH, Ikpatt OF, Fan YS, Barredo JC, **Vega F**, Chapman FR. Primary mediastinal large B-cell lymphoma with translocations involving BCL6 and MYC. *Am J Clin Pathol* 145:710-6; 2016 PMID: 27124935
14. Bueso-Ramos CE, Medeiros LJ, **Vega F**. Introduction to the 2013 workshop of the society for hematopathology/European association for hematopathology. *Am J Clin Pathol* 144:4-5; 2015 PMID:26071457
15. Samaniego F, Hagemester F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, **Vega F**, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B cell lymphomas. *Br J Haematol* 169:814-23; 2015. PMID: 25828695
16. Ruiz-Cordero R, Chapman J, **Vega F**. Synaptophysin is frequently expressed in megakaryocytes: a novel immunohistochemical finding of unknown significance. *Rev LatinoAmer Patol Clin* 62:76-80; 2015.
17. Chapman-Fredricks J, Gentles A, Sujoy V, **Vega F**, Dumar C, Blevins T, Bernal-Mizrachi L, Mosunjac M, Pimentel A, Zhu D, Lossos I. Gene Expression Analysis of Plasmablastic Lymphoma Identifies Down Regulation of B Cell Receptor Signaling and Additional Unique Transcriptional Programs. *Leukemia* 29:2270-3;2015. PMID: 25921246
18. Blonska M, Agarwal N, **Vega F**. Shaping of the tumor microenvironment: stromal cells and vessels. *Semin Cancer Biol* 34:3-13; 2015. PMID: 25794825
19. Ruiz-Cordero, R, Lewis J, Blieden C, Campuzano-Zuluaga G, Hernandez J, Lossos IS, Ikpatt F, Chapman JR, **Vega F**. Unusual immunophenotypic variant of large B-cell lymphoma associated with HHV-8 and EBV in an HIV positive patient. *Hum Path: Case Reports* 2:49-54; 2015.
20. Zhu D, Bhatt S, Lu V, Guo F, Veelken H, Hsu D, Liu F, Cubela S, Kunkalla K, **Vega F**, Chapman-Fredricks J, and Lossos I. Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas express self polyreactive B cell receptors. *Leukemia* 29:1587-99; 2015 PMID: 25676418
21. Blonska M, Zhu Y, Chuang HH, You JM, Kunkalla K, **Vega F**, Lin X. Jun-regulated genes promote interaction of diffuse large B cell lymphoma with the microenvironment. *Blood* 125:981-91; 2015 PMID: 25533033

22. **Vega F**, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid Neoplasms associated with rearrangements of *PDGFR-A*, *PDGFR-B* and *FGFR1*. *Am J Clin Pathol* 144:377-92; 2015. PMID:26276769
23. Blieden C, Fan YS, Chapman JR, **Vega F**. De novo acute myeloid leukemia with monocytoid blasts and erythrophagocytosis. *Clin Case Rep* 2:333-5; 2014
24. Blieden C, Campuzano-Zuluaga G, Moul A, Chapman JR, Cioffi-Lavina, Ikpat OF Byrne GE, **Vega F**. Anaphylactic Reaction to Platelet Transfusion as the Initial Symptom of an Undiagnosed Systemic Mastocytosis: A Case Report and Review of the Literature. *J Med Case Rep* 26;8:389; 2014
25. Blieden C, Medeiros LJ, **Vega F**. Acquired B-cell immunophenotype of follicular dendritic cells in a B-cell depleted lymph node after treatment with rituximab *Ann Hematol* 93:1947-8; 2014
26. Chapman-Fredricks J, Sandoval-Sus J, **Vega F**, Lossos IS. Progressive Leukemic Non-nodal Mantle Cell Lymphoma Associated with Deletions of TP53, ATM, and / or 13q14. *Ann Diagn Pathol* 18:214-9, 2014
27. Gera S, Dekmezian MS, Duvic M, Tschen J, **Vega F**, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement. *Am J Dermatopathol* 36:244-51; 2014.
28. Cho-Vega JH, **Vega F**, CD30-negative lymphomatoid papulosis type D in an elderly man. *Am J Dermatopathol* 36:190-2, 2014.
29. Leventaki V, Oki Y, Romaguera J, **Vega F**. Indolent Peripheral T-Cell Lymphoma Involving the Gastrointestinal Tract. *Human Pathol* 45:421-6, 2014.
30. Oki Y, Westin JR, **Vega F**, Chuang H, Fowler N, Neelapu S, Hagemester FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orłowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. *Br J Haematol* 163:611-20, 2013.
31. Merrit BY, Curry JL, Duvic M, **Vega F**, Sheehan AM, Curry CV. Pediatric subcutaneous panniculitis-like T-cell lymphoma with features of hemophagocytic syndrome. *Pediatr Blood Cancer* 60:1916-7, 2013.
32. Handal B, Entow R, Lara D, Bailey M, **Vega F**, Hu P, Lennon A. Investigating the expression of oncogenic and tumor suppressive microRNA in DLBCL. *J Assoc Genet Technol* 39: 14-20; 2013.

33. Sánchez-Espiridión B, Martín-Moreno AM, Montalbán C, Figueroa V, **Vega F**, Younes A, Medeiros LJ, Alvés FJ, Canales M, Estévez M, Menarguez J, Sabín P, Ruiz-Marcellán MC, Lopez A, Sánchez-Godoy P, Burgos F, Santonja C, López JL, Piris MA, Garcia JF. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. *Br J Haematol* 162:336-47, 2013.
34. Jain P, **Vega F**, Faderl S. “Cup-like” blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML). *Int J Hematol* 98:3; 2013.
35. Qu C, Liu Y, Kunkalla K, Sing RR, Blonska, M, Lin X, Agarwal NK, **Vega F**. Trimeric G protein-CARMA1 axis links smoothed, the hedgehog receptor transducer, to NF- κ B activation in diffuse large B-cell lymphoma. *Blood* 121:4718-28, 2013.
36. Agarwal NK, Qu C, Kunkalla K, Liu Y, **Vega F**. Transcriptional regulation of Serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. *J Biol Chem* 288:15390-401, 2013
37. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandaythapani V, Luong A, **Vega F**, Fowler N, Dong C, Davis E, Neelapu SS. Cross talk between follicular helper T cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. *J Immunol* 190:6681-93, 2013.
38. **Vega F**. Time to look for CD30 expression in diffuse large B cell lymphomas, along the way to immunotherapy. *Leuk Lymphoma* 54:2341-2; 2013.
39. Kunkalla K, Liu Y, Changju Q, Leventaki V, Agarwal NK, Singh R, **Vega F**. Functional Inhibition of BCL2 is needed to Increase the Susceptibility to Apoptosis to SMO Inhibitors in Diffuse Large B-Cell Lymphoma of Germinal Center Subtype. *Ann Hematol* 92:777-87, 2013.
40. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, Konoplev S, Bueso-Ramos CE, **Vega F**, Medeiros LJ, Yin CC. Extranodal NK/T cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. *Am J Surg Pathol* 37:14-23, 2013.
41. Kanagal-Shamanna R, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, Penn GM, Young KH, You MJ, **Vega F**, Bassett R, Miranda RN. High-grade B cell lymphoma unclassifiable, with blastoid feature: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. *Histopathology* 61:945-54, 2012.
42. Greaves WO, Xiao L, Sanchez-Espiridion B, Kunkalla K, Dave KS, Liang CS, Singh RR, Younes A, Medeiros LJ, **Vega F**. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. *J Hematol Oncol* 5:47, 2012. PMID:3470996

43. Ramirez E, Singh RR, Kunkalla K, Liu Y, Cain C, Multani AS, Lennon PA, Jackacky J, Dawud S, Gu J, Yang S, Hu PC, **Vega F**. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma. *Leuk Res* 36:1267-73, 2012.
44. Buglio D, Palakurthi S, Byth K, **Vega F**, Toader D, Saeh J, Neelapu SS, Younes A. Essential role of TAK1 in regulating mantle cell lymphoma survival. *Blood* 120:347-55, 2012
45. Li C, Thompson MA, Tamayo AT, Zuo Z, Lee J, **Vega F**, Ford RJ, Pham LV. Over-expression of thioredoxin-1 mediates growth, survival, and chemoresistance and is a drugable target in diffuse large B-cell lymphoma. *Oncotarget* 3:314-26, 2012. PMID:3359887
46. Kim K, Leventaki L, Bhajjee F, Jackson CC, Medeiros LJ, **Vega F**. Extracavitary/Solid Variant of Primary Effusion Lymphoma. *Ann Diagn Pathol* 16:441-6, 2012.
47. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Medeiros LJ, **Vega F**, Younes A, Piris MA, Garcia JF. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. *Haematologica* 97:1080-4, 2012. PMID:3396681
48. Meadows SA, **Vega F**, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ. PI3K δ inhibitor, GS-1101(CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. *Blood* 119:1897-900, 2012
49. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, **Vega F**. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. *Mod Pathol* 25:231-6, 2012.
50. Ok CH, Singh RR, **Vega F**. Aberrant activation of hedgehog signaling pathway in hematological neoplasms. *Am J Pathol* 180:2-11, 2012. PMC 3338341
51. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, **Vega F**, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin-type lymphomas. *Hum Pathol* 42:1117-24, 2011.
52. Cho-Vega JH, **Vega F**. CD4 CD8 Double-Negative Early Stage Mycosis Fungoides Associated with Primary Cutaneous Follicular Center Lymphoma. *J Am Acad Dermatol* 65:884-6, 2011.

53. Drakos E, Singh RR, Rassidakis GZ, Schlette EJ, Li J, Claret FX, Ford RJ, **Vega F**, Medeiros LJ. Activation of p53 pathway by MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma. *Leukemia* 25:856-67, 2011.
54. Singh R, Kunkalla K, Qu C, Schlette E, Neelapu S, Samaniego F, **Vega F**. ABCG2 is a Direct Transcriptional Target of Hedgehog Signaling and Involved in Stroma-Induced Drug Tolerance in Diffuse Large B-Cell Lymphoma. *Oncogene* 30:4874-86, 2011. PMID:3165099
55. Curry LJ, Prieto VG, Jones DM, **Vega F**, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome. *J Cutan Pathol* 38:295-7, 2011.
56. Greaves WO, Kim JE, Singh RR, Drakos E, Kunkalla K, Sánchez-Espiridión B, Garcia JF, Medeiros LJ, **Vega F**. Glioma associated oncogene homologue 3 (GLI3), a hedgehog transcription factor, is highly expressed in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. *Hum Pathol* 42:1643-52, 2011. PMID:3165071
57. Hsu C, **Vega F**, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and associated myasthenia gravis: true, true, related? *J Clin Oncol* 29:369-71, 2011.
58. Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, **Vega F**, Medeiros LJ, Ford RJ. Constitutive BR3 receptor signaling in diffuse large B-cell lymphomas stabilizes NK- κ B-inducing kinase, while activating both canonical and alternative NF- κ B pathways. *Blood* 117:200-10, 2011. PMID: 3037744.
59. Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, **Vega F**, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. *Am J Clin Path* 135:686-96, 2011.
60. Vishwamitra D, Shi P, Wilson D, Manshoury R, **Vega F**, Schlette EJ, Amin HM. Expression and effects of inhibition of IGF-IR tyrosine kinase in mantle cell lymphoma. *Haematologica* 96:871-90, 2011. PMID:3105649.
61. **Vega F**, Medeiros LJ. V(D)J recombination and staggered DNA breaks: guilty again. *Blood* 115:2121-2, 2010.
62. Wang SA, Jabbark, Lu G, Chen SS, Galili N, **Vega F**, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. *Leukemia* 24:740-7, 2010.
63. **Vega F**, Davuluri Y, Cho-Vega JH, Ma S, Wang RU, Multani AS, Drakos I, Pham L, Shen L, Ambrus J, Medeiros LJ, Ford R. Side population contains cells with

"tumor-initiating cell" features responsible for lymphoma maintenance and systemic dissemination. *J Cell Mol Med* 14:1532-45, 2010.

64. Singh RR, Kim JE, Davuluri Y, Drakos-E, Cho-Vega JH, Amin H, **Vega F**. Hedgehog-signaling pathway contributes to tumor cell survival and proliferation in diffuse large B-cell lymphoma. *Leukemia* 24:1025-36, 2010.

65. Cho-Vega JH, Tschen J, Duvic M, **Vega F**. Early stage mycosis fungoides variants: Case based review. *Ann Diagn Pathol* 14:369-85, 2010.

66. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen J, Bueso-Ramos C, Medeiros LJ, **Vega F**. Angioimmunoblastic T-Cell Lymphoma in Bone Marrow: A Morphologic and Immunophenotypic Study. *Hum Pathol* 41:79-87, 2010.

67. Singh RR, Cho-Vega JH, Davuluri y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, **Vega F**. Sonic Hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. *Cancer Res* 69:2550-8, 2009.

68. Drakos E, Rassidakis RZ, Leventaki V, Cotta C, **Vega F**, Medeiros LJ. Nodular Lymphocyte predominant Hodgkin lymphoma with clusters of L&H-like cells, acute inflammation, and fibrosis: a syncytial variant. *Am J Surg Pathol* 33:1725-31, 2009.

69. Falchook G, **Vega F**, Dang N, Samaniego F, Rofriguez M, Champlin R, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. *Ann Oncol* 20:1080-1085, 2009.

70. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Fayad L, Medeiros LJ, **Vega F**. Hedgehog (SHH)-signaling proteins and ATP binding cassette (ABC) are aberrantly expressed in diffuse large B-cell lymphoma. *Mod Pathol* 10:1312-20, 2009.

71. Jain N, Hubbard J, **Vega F**, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature. *Clin Leuk* 2:64-67, 2008.

72. **Vega F**, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, Jones D, Medeiros LJ, Luthra R. Splenic Marginal Zone Lymphomas are characterized by loss of Interstitial Regions of Chromosome 7q,7q31.32 and 7q36.2, that include protection of Telomere 1 (POT1) and Sonic Hedgehog (SHH) Genes. *Br J Haematol* 142:216-226, 2008.

73. Huh Yang, I-Chun Lin K, **Vega F**, Schlette E, Yin C, Keating M, Luthra R, Medeiros LJ and Abruzzo L. MYC translocation in chronic lymphocytic leukemia is associated with increased prolymphocytes and a poor prognosis. *Br J Haematol* 142:36-44, 2008.

74. Cho-Vega JH, Medeiros LJ, Prieto VG, **Vega F**. Leukemia Cutis. *Am J Clin*

Pathol 129:130-42, 2008.

75. Cho-Vega JH, **Vega F**, Medeiros LJ. An Attractive Therapeutic Target, mTOR Pathway, for an Effective Combinatorial Cancer Therapy in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. *Adv Anat Pathol* 15:105-12, 2008.

76. Quintas-Cardama A, Tong W, Manshour T, **Vega F**, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human nup214-abl-positive T-cell malignancies. *Leukemia* 22:1117-1124, 2008.

77. **Vega F**, Medeiros LJ, Davuluri R, Alkan S, Abruzzo LV. t(8;13)-positive bilineal lymphomas:report of six cases. *Am J Surg Pathol* 32:14-20, 2008.

78. **Vega F**, Medeiros LJ, Gaulard P. Hepatosplenic and other gamma delta T-cell Lymphomas. *Am J Clin Pathol* 127:869-80, 2007.

79. Cho-Vega JH, **Vega F**, Schwartz MR, Prieto VG. Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions:morphological studies supporting cell adhesion function of DCXR. *J Cutan Pathol* 34:535-542, 2007.

80. **Vega F**, Coombes KR, Thomazy VA, Patel K, Lang W, Jones D. Tissue-Specific Function of Lymph Node Fibroblastic Reticulum Cells. *Pathobiology* 73:71-81, 2006.

81. **Vega F**, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ. Systemic lymphomas involving the pleura. A Clinicopathologic study of 34 cases diagnosed by pleural biopsy. *Arch Pathol Lab Med* 130:1497-1502, 2006.

82. Cho-Vega JH, **Vega F**, Rassidakis G, Medeiros LJ. Primary Cutaneous Marginal Zone B-Cell Lymphoma. *Am J Clin Pathol* 125:S38-S49, 2006.

83. **Vega F**, Chang CC, Schwartz MR, Verm R, Preti HA, Etwon A, Younes M, Jaffe ES. Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease. *Am J Surg Pathol* 4:539-544, 2006.

84. **Vega F**, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mTOR Signaling Pathway Contributes to Tumor Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma. *Cancer Res* 66:6589-97, 2006.

85. Lin P, Jones D, Medeiros LJ, Chen W, **Vega F**, Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. *Am J Clin Pathol* 126:1-4, 2006.

86. **Vega F**, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch C, Vilchez RA, McGregor DK, Jorgensen JL. Plasmablastic lymphomas and plasmablastic

plasma cell myeloma have nearly identical immunophenotypic profiles. *Mod Pathol* 18:806-815, 2005.

87. **Vega F**, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. *Ann of Diagn Pathol* 9:340-350, 2005.

88. Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurgers K, Remache YK, **Vega F**, Goy AH, Gilles F, Medeiros LJ. Suppressor of cytokine signaling 3 expression in anaplastic cell lymphoma. *Leukemia* 18:1872-1878, 2004.

89. Thomazy VA, **Vega F**, Medeiros LJ, Davis PJ, Jones D. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: transglutaminase reveals coordinate regulation. *Am J Pathol* 163:165-174, 2003. PMID:1868169

90. **Vega F**, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. *Arch Pathol Lab Med* 127:1148-1160, 2003.

91. **Vega F**, Medeiros LJ, Lang WH, Mansoor A, Bueso-Ramos C, Jones D. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumors. *Br J Haematol* 117:569-576, 2002.

92. Sanchez-Vega B, **Vega F**, Hai S, Medeiros LJ, Luthra R. Real-time t(14;18) PCR assay combined with high resolution PCR fragment analysis: A novel approach to monitor disease/tumor burden in follicular lymphoma patients. *Mod Pathol* 15:441-453, 2002.

93. **Vega F**, Medeiros LJ, Luthra R. Taqman PCR in the detection and of chromosomal translocations in follicular lymphoma, mantle cell lymphoma and chronic myeloid leukemia. *Internet J Pathol* 2(1), 2002.

94. **Vega F**, Orduz R, Medeiros LJ. Roles of common chromosomal translocations in non-Hodgkin's lymphomas. *Pathology* 34:397-409, 2002.

95. Abruzzo LV, Rosales CM, Medeiros LJ, **Vega F**, Luthra R, Manning JT, Keating MJ, Jones D. Related Articles Epstein-Barr virus positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. *Am J Surg Pathol* 26:630-636, 2002.

96. Sanchez-Vega B, **Vega F**, Medeiros LJ, Lee MS, Luthra R. Quantification of BCL-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. *J Mol Diagn* 4:223-229, 2002. PMID:1907359

97. Onciu M, Lai R, **Vega F**, Bueso-Ramos C, Medeiros LJ. Precursor T-cell acute lymphoblastic leukemia in adults. *Am J Clin Pathol* 117:252-258, 2002.

98. Stancu M, Jones D, **Vega F**, Medeiros LJ. Peripheral T-cell lymphoma arising in the liver. *Am J Clin Pathol* 118:574-581, 2002.
99. Sen F, **Vega F**, Medeiros LJ. Molecular genetic methods in the diagnosis of hematologic neoplasms. *Semin Diagn Pathol* 19:72-93, 2002.
100. **Vega F**, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. *Blood* 100:3369-3373, 2002.
101. Jones D, **Vega F**, Sarris AH, Medeiros LJ. A CD4 and CD8 "double-negative" immunophenotype in cutaneous T-cell lymphoma is predictive of an aggressive clinical course. *Am J Surg Pathol* 26:225-231, 2002.
102. Calvo M, Firvida JL, **Vega F**, Salgado M, Garcia Mata J, Ruben M, Barreiro A. Wilms tumor in the adult. *Arch Esp Urol* 54:370-374, 2001.
103. **Vega F**, Medeiros LJ, Abruzzo LV. Primary paratesticular lymphoma: a report of two cases and literature review. *Arch Patol Lab Med* 125:428-432, 2001.
104. **Vega F**, Medeiros LJ. Marginal zone B-cell lymphoma of extranodal MALT-type. Molecular genetics provides new insights into pathogenesis. *Adv Anat Pathol* 8:313-326, 2001.
105. **Vega F**, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, Abruzzo LV. Hepatosplenic T-cell lymphoma in bone marrow: An intra-sinusoidal neoplasm with blastic cytologic features. *Am J Clin Pathol* 116:410-419, 2001.
106. **Vega F**, Medeiros LJ. Chromosomal translocations in Non-Hodgkin's lymphomas (Part II). *Patologia* 34:353-366, 2001.
107. **Vega F**, Medeiros LJ. Chromosomal translocations in Non-Hodgkin's lymphomas (Part I). *Patologia* 34:277-286, 2001.
108. **Vega F**, Medeiros LJ, Jones D, Abruzzo LV, Lai R, Manning J, Dunmire V, Luthra R. A novel 4-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. *Am J Clin Pathol* 116:17-24, 2001.
109. Olivieri DN **Vega F**. Image prototype similarity matching for lymph node hemopathology. *Proceedings - International Conference on Pattern Recognition* 2000;15(2):279-282.
110. Panizo A, Sola I, **Vega F**, de Alava E, Lozano MD, Idoate MA, Pardo-Mindan FJ. Predicting metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle regulatory proteins. *Int J Surg Pathol* 8:133-144, 2000.

111. Rodriguez-Gomez M, Fernandez-Sueiro JL, Willisich A, Fernandez-Dominguez L, Lopez-Barros G, **Vega F**. Multifocal dactylitis as the sole clinical expression of sarcoidosis. *J Rheumatol* 27:245-247, 2000.
112. **Vega F**, Diaz MS. Extramedullary hematopoiesis in polyposis. *Gastrointest Endosc* 51:330-331, 2000.
113. **Vega F**, Panizo A, Diez, Pardo-Mindan FJ. Susceptibility to apoptosis of arterioles and capillaries in adult spontaneously hypertensive rats. *Am J Hypertens* 12:815-820, 1999.
114. **Vega F**, Lozano MD, Alcade J, Pardo-Mindan FJ. Role of the immunohistochemical and molecular biology in necrotic lymph node. *Virchows Arch* 434:245-248, 1999.
115. Pastrana J, Conchillo MA, **Vega F**, Beloqui O. Granulomatosis linfomatoide pulmonar asociada a SIDA. Descripcion de un caso y revision de la literatura. *An Med Interna* 15:487-489, 1998.
116. Panizo A, **Vega F**. Revision de la tecnica del TUNEL. *Patologia* 30:243-245, 1997.
117. **Vega F**, Errasti F, Pardo-Mindan FJ. Renal transplantation from a donor with a Nail-Patella syndrome. *Nephrol Dial Transp* 12:1742-1744, 1997.
118. Arriagada C, Leyes, M, Valenti JR, **Vega F**. Papel de la artroscopia en la condrocalcinosis. *Cuadern Artroscopia* 4:21-25, 1997.
119. Panizo A, **Vega F**. Glosario de biologia molecular. *Patologia* 30:259-260, 1997.
120. Perez-Requena J, **Vega F**, Guezmez Domingo A, Ruiz ML, Paloma Gonzalez MJ, Diaz I. Gliomatosis peritoneal: presentacion de dos casos asociados a gliomatosis ganglionar y ovarica y elevacion de las concentraciones de alfa-fetoproteina. *Patologia* 30:150-153, 1997.
121. Idoate MA, **Vega F**. Diagnostico de las enfermedades neurometabolicas y neurodegenerativas mediante biopsia cutanea. *Rev Neurol* 25:S269-S280, 1997.
122. Diez J, Panizo A, Hernandez M, **Vega F**, Sola I, Fortuno MA, Pardo J. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. *Hypertension* 30:1029-1034, 1997.
123. Arias M, Abreu JA, Iglesias A, Longo J, Lecumberri F, **Vega F**. Primary amyloidosis presenting as renal infarction. *Eur-Radiol* 6:346-8, 1996.

124. Garcia-Rayo S, Gurrpide A, **Vega F**, Brugarolas A. Regresion tumoral espontanea en un paciente con mieloma multiple. Comunicacion de un caso adicional. Rev Med Univ Navarra 40:27-30, 1996.
125. **Vega F**, Sierrasesumaga L, Panizo A, Diaz L, Foncillas J. Metastasis Pulmonares de Osteosarcoma: Factores pronosticos. Patologia 29:325-331, 1996.
126. **Vega F**, Diaz L, Castro I, Panizo A, Sierrasesumaga L, Pardo-Mindan FJ. Metastasis ganglionares de osteosarcomas. Rev Med Univ Navarra 40:27-30, 1996.
127. **Vega F**. Pseudomixoma Peritonei. Rev Med Univ Navarra 2:64, 1996.
128. **Vega F**. Adenocarcinoma de Sigma. Rev Med Univ Navarra 40:190, 1996.
129. **Vega F**, Pardo-Mindan FJ. Carcinoma Gastrico de Celulas en Anillo de Sello. Rev Med Univ Navarra 39:47; 1995.
130. **Vega F**, Pardo-Mindan FJ. Carcinoma Difuso Gastrico. Rev Med Univ Navarra 39:84, 1995.
131. Gimeno Ballester J, Ruza-Paz Curbera E, Crespo Cuadrado E, Azcona San Julian C, **Vega F**, Sierrasesumaga L. Actualizacion de la Hepatitis C. A proposito de un caso. Bol S Vasco-Nav Ped 89:79-85; 1995.
132. **Vega F**, Pardo-Mindan FJ. Quiste Hidatidico Hepatico. Cir Iber Americana 3:62, 1994.
133. **Vega F**, Pardo-Mindan FJ. Colecistitis Cronica Esclerosante. Rev Med Univ Navarra 39:30, 1994.
134. **Vega F**, Pardo-Mindan FJ. Carcinoma Ductal Infiltrante de Mama. Cir Iber Americana 3:127, 1994.

20. Other Works, Publications, and Abstracts:

Letters to the Editor

1. **Vega F**. Uterine Rupture. N Eng J Med 339:268-269, 1998.
2. Lamela J, **Vega F**, Blanco J. Airway obstruction in chronic obstructive pulmonary disease. N Eng J Med 351:1459-1461, 2004.
3. Lamela J, **Vega F**. Immunologic aspects of chronic obstructive pulmonary disease. N Eng J Med 361:1024, 2009.

Abstracts in National and International Meetings

- 1.-Idoate MA, Vázquez JJ, **Vega F**, de Vicente J. Extracutaneous tumour metastasis in the skin. *XVth European Congress of Pathology. Copenhagen, Denmark, September 1995.*
- 2.-Pardo-Mindán FJ, Hernández M, Panizo A, **Vega F**, Díez J. Accumulation of fibronectin in the aorta of spontaneously hypertensive rats with increased ACE activity. Impact on the biochemical characteristics of smooth muscle cells. *European Society of Cardiology. Birmingham. United Kingdom. August 1996.*
- 3.-Sola I, Pardo-Mindán FJ, Panizo A, **Vega F**, Díaz L. P53 nuclear accumulation and proliferative activity as prognostic factors in Dukes B & C colon carcinomas. *85th Annual Meeting, Washington, D.C. United States and Canadian Academy of Pathology. March, 1996.*
- 4.-Pardo-Mindán FJ, Panizo A, Díez J, Sola I, Reed JC, Krahewski S, **Vega F**. Is the stimulation of the apoptotic-preventing signal bcl-2 involved in hyperplasia of smooth muscle cells in coronary arteries of spontaneously hypertensive rats?. *85th Annual Meeting, Washington, D.C. United States and Canadian Academy of Pathology. March, 1996.*
- 5.-Patiño A, Riol M, Antillon F, de Alava E, **Vega F**, Sierrasesúmaga L. Involvement of the p53 and p16 tumor suppressor genes in the development of pediatric bone tumors. *International Society of Paediatric Oncologic (SIOP) XXVIIIth Meeting. Vienna. October, 1996.*
- 6.-Leyes M, **Vega F**, Villas C. Root compression by cystic lesions arising from the lumbar facet joints. Repor of four cases. *III Congress of the European Federation of National Associations of Orthopaedics and Traumatology. Barcelona, April, 1997.*
- 7.-**Vega F**, Panizo A, Díaz L, Pardo-Mindán FJ, Hernandez M, Diez J. Effects of quinapril on the prevention and regression of aortic hypertensive structural remodeling. *86th Annual Meeting, Orlando. United States and Canadian Academy of Pathology. March, 1997.*
- 8.-Lozano MD, Panizo A, **Vega F**, Okafor OC, Díaz L. The role of endomyocardial biopsy in the diagnosis of chronic rejection in heart transplantation. *86th Annual Meeting, Orlando. United States and Canadian Academy of Pathology. March, 1997.*
- 9.-Panizo A, Sola I, de Alava E, Díaz L, **Vega F**. Expression of cell cycle regulatory proteins (p53, c-Myc, bcl-2) in gastrointestinal stromal tumors, correlation with proliferation, histological features and clinical outcome. *86th Annual Meeting, Orlando. United States and Canadian Academy of Pathology. March, 1997.*
- 10.-**Vega F**, Sastre JL, Pazos R. Coagulative necrosis like residual splenic mass after treatment in a patient with non-Hodgkin's lymphoma: value of immunohistochemistry. *On-line Proceedings of the 5th Internet World Congress on Biomedical Sciences '98 at*

McMaster University, Canada (available from URL: <http://www.mcmaster.ca/inabis98/symposia>).

11.-Panizo A, **Vega F**, de Alava E, Díaz L, Pardo-Mindán FJ. Apoptosis and fibronectin accumulation in myocardial cells in early infarction non-cardiogenic shock and eosinophilic heart disease. *87th Annual Meeting, Boston. United States and Canadian Academy of Pathology. February, 1998.*

12.-**Vega F**, Lozano MD, Okafor OC, Fernández J, Pardo-Mindán FJ. Utility of immunophenotypic studies in necrotic tissues. *87th Annual Meeting, Boston. United States and Canadian Academy of Pathology. February, 1998.*

13.-**Vega F**, Panizo A, Toledo G, Díaz L, Díez J, Pardo-Mindán FJ. Susceptibility to apoptosis of vascular smooth muscle cells of adult spontaneously hypertensive rats. *87th Annual Meeting, Boston. United States and Canadian Academy of Pathology. February, 1998.*

14.-**Vega F**, Medeiros LJ, Jones D, Abruzzo LV, Lai R, Manning J, Dunmire V, Metha P, Luthra R. A novel 4-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. *Trainee Recognition Day and Research Exposition 2001. The University of Texas. M.D. Anderson Cancer Center. Houston April, 2001*

15.-**Vega F**, Luthra R, Medeiros LJ, Dunmire V, Jones D. A molecular approach to monitoring disease progression in mycosis fungoides. *Trainee Recognition Day and Research Exposition 2001. The University of Texas. M.D. Anderson Cancer Center. Houston April, 2001.*

16.-**Vega F**, Lai R, Luthra R, Duvic M, Ibrahim S, Lang WH, Medeiros LJ, Jones D. Differentiating benign dermatopathic changes from tumor infiltrates in lymph nodes of cutaneous T-cell lymphoma (CTCL). *90th Annual Meeting, Atlanta. United States and Canadian Academy of Pathology. March, 2001.*

17.-Jones D, **Vega F**, Dunmire V, Medeiros LJ, Luthra R. A molecular approach to monitoring disease progression in mycosis fungoides. *90th Annual Meeting, Atlanta. United States and Canadian Academy of Pathology. March, 2001.*

18.-**Vega F**, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Abruzzo LV. Hepatosplenic $\gamma\delta$ T-cell lymphoma (HSTCL) in bone marrow: An intra-sinusoidal neoplasm with blastic cytologic features. *90th Annual Meeting, Atlanta. United States and Canadian Academy of Pathology. March, 2001.*

19.-**Vega F**, Medeiros LJ, Dunmire V, Jones D, Manning J, Abruzzo LV, Luthra R. Characterization of TCR γ -gene rearrangements patterns in T-cell lymphomas: a four color multiplex PCR and GeneScan (GS) Analysis. *90th Annual Meeting, Atlanta. United States and Canadian Academy of Pathology. March, 2001.*

- 20.-Sanchez-Vega B, **Vega F**, Hai S, Medeiros LJ, Luthra R. TaqMan real-time PCR combined with capillary electrophoresis: a novel and rapid approach that allows quantification and accurate size determination of *bcl-2/JH* fusion sequences. *91th Annual Meeting, Chicago. United States and Canadian Academy of Pathology. February, 2002.*
- 21.-Thomazy VA, **Vega F**, Medeiros LJ, Davies PJ, Jones D. Tissue transglutaminase expression uncovers coordinate phenotypic regulation of several cell types in the paracortex of normal and neoplastic lymph nodes. *91th Annual Meeting, Chicago. United States and Canadian Academy of Pathology. February, 2002.*
- 22.-**Vega F**, Medeiros LJ, Thomazy VA, Lang WH, Mansoor A, Bueso-Ramos C, Jones D. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumors. *91th Annual Meeting, Chicago. United States and Canadian Academy of Pathology. February, 2002.*
- 23.-**Vega F**, Lang WH, Medeiros LJ, Patel K, Coombes K, Jones D. Microarray transcriptional analysis of cultured lymph node reticular cells and their responses to lymph-derived cytokines. *91th Annual Meeting, Chicago. United States and Canadian Academy of Pathology. February, 2002.*
- 24.-**Vega F**, Coombes K, Patel K, Abruzzo LV, Jones D. Transcriptional profiling of lymph node stroma: comparing tumors and cell lines of follicular dendritic cell and fibroblastic reticular cell lineages. *44th American Association of Hematology. Philadelphia, December, 2002.*
- 25.-Baena J, Sola I, Toledo G, **Vega F**, de Alava E, Lozano MD, Idoate MA, Pardo-Mindan FJ. Mucosa-Associated Lymphoid Tissue (MALT) lymphoma of the stomach: evaluation of the accompanying morphological alterations of the gastric mucosa. *92th Annual Meeting, Washington. United States and Canadian Academy of Pathology. March, 2003.*
- 26.-**Vega F**, Cano P, Sanchez-Vega B, Lopez-Alvarez E, Hayes K, Glassman A, Kantarjian H, Medeiros LJ, Luthra R. Comprehensive correlation of conventional cytogenetics, FISH and quantitative real-time reverse transcriptase PCR results for detecting t(9;22) in chronic myeloid leukemia (CML) patients. *92th Annual Meeting, Washington. United States and Canadian Academy of Pathology. March, 2003.*
- 27.-**Vega F**, Chang CC, McGregor DK, Finch C, Killen D, Jorgensen JL. Immunophenotypic profile cannot differentiate between plasmablastic lymphoma and the plasmablastic variant of extramedullary plasmacytoma. *93th Annual Meeting, Vancouver. United States and Canadian Academy of Pathology. March, 2004.*

- 28.-**Vega F**, Medeiros LJ, Atwell C, Claret FX, Rassidakis GZ. Activation of mTOR and its downstream effectors in ALK+ anaplastic large cell lymphoma (ALCL). *94th Annual Meeting, San Antonio. United States and Canadian Academy of Pathology. February, 2005.*
- 29.-**Vega F**, Jaffe ES, Ewton A, Schwartz MR, Verm R, Preti HA, Younes M, Chang CC. **T- and NK-cell lymphomas Workshop 2005 Society of Hematopathology/European Association of Hematopathology. Houston, October, 2005.**
- 30.-**Vega F**, Medeiros LJ, Atwell C, Cho JH, Tian L, Claret FX, Rassidakis GZ, Activation of mTOR Signaling Pathway Contributes to Tumoral Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma. *47th American Association of Hematology. Atlanta, December, 2005.*
- 31.-**Vega F**, Medeiros LJ, Abruzzo LV. t(8;13) Positive Bilineage Lymphomas with T-Cell and Myeloid Components: Report of 4 Patients with the 8p11 Myeloproliferative Syndrome (EMS). *95th Annual Meeting, Atlanta. United States and Canadian Academy of Pathology. February, 2006.*
- 32.-Cho-Vega JH, **Vega F**, Schwartz MR, Prieto VG. Expression of dicarbonyl/L-xylulose reductase (DCXR), a novel cell adhesion molecule, in melanocytic lesions. *Lab Invest 86:78A, 2006.*
- 33.-**Vega F**, Medeiros LJ, Abruzzo LV. t(8;13) positive "Bilineage lymphomas" with T Cell and myeloid components: Report of 4 patients with the 8p11 myeloproliferative syndrome (EMS). *Lab Invest 86:249A-50A, 2006.*
- 34.-**Vega F**, Lennon PA, Luthra M, Jones D, Breeden M, Cho J, Medeiros L, Luthra R. Array-based comparative genomic hybridization (aCGH) of splenic and nodal marginal zone lymphomas (MZLs). *Mod Pathol 20:262A, 2007.*
- 35.-Tan M, Chen W, Jones D, Leventaki V, Medeiros LJ, **Vega F**. Histological and immunophenotypical characterization of angioimmunoblastic T-cell lymphoma (AILT) involving the bone marrow. *Mod Pathol 20:261A-62A, 2007.*
- 36.-Huh Y, **Vega F**, Schlette E, Medeiros LJ, Abruzzo LV. *MYC* gene translocation in chronic lymphocytic leukemia. *Lab Invest 87:245A, 2007.*
- 37.-Konoplev S, Nguyen M, Huang X, Rassidakis GZ, Garcia-Manero G, Yin CC, Amin H, Schlette E, Lin P, **Vega F**, Admirand J, Huh Y, You J, Jorgensen JL, Kantarjian HM, Medeiros LJ, Bueso-Ramos C. Cytoplasmic expression of nucleophosmin does not predict favorable prognosis in AML patients. *Lab Invest 88:260A, 2008.*

- 38.-Cho-Vega JH, Davuduri R, Rivell G, Wang RY, Multani AS, Medeiros LJ, Ford RJ, **Vega F**. Identification and characterization of lymphoma stem cells in non-Hodgkin lymphoma cell lines. *Mod Pathol* 21:249A, 2008.
- 39.-Cho-Vega JH, Singh RR, Luthra R, Ma S, Davuluri Y, Drakos E, Rassidaki GZ, Medeiros LJ, **Vega F**. Sonic hedgehog signaling is activated by NPM/ALK in ALK-positive anaplastic large cell lymphomas. *Lab Invest* 88:249A, 2008.
- 40.-Milito C, Khokhar FA, Newton K, Singh RR, Kasbidi F, Schlette E, Yao H, Biasoli I, Medeiros LJ, Jones D, Luthra R, **Vega F**. Extra Copies of GLI1 Gene at 12q13.12 Are Detected in a Subset of Cases of Trisomy 12 Negative Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomas. *Lab Invest* 89:277A, 2009.
- 41.-Kim JE, Singh RR, Milito C, Cho-Vega JH, Karanikou M, Kasbidi F, Medeiros LJ, Luthra R, **Vega F**. Sonic Hedgehog Signaling Pathway as a Therapeutic Target in Diffuse Large B-Cell Lymphoma. *Mod Pathol* 22:271A, 2009.
- 42.-Huh YO, Ketterling RP, **Vega F**, Kim JE, Medeiros LJ, Abruzzo LV. The t(14;19)(q32; q13)-Positive B-Cell Leukemia: A Comprehensive Genetic and Clinicopathologic Study of Six Cases. *Mod Pathol* 89:268A, 2009.
- 43.-Singh R, Kim JE, **Vega F**. The ATP-binding cassette transporter ABCG2 is transcriptionally regulated by Sonic Hedgehog signaling pathway, American Association for Cancer Research (AACR), Denver, 4/2009
- 44.-Singh R, Kim JE, Kunkalla K, **Vega F**. Hedgehog signaling is a therapeutic target in diffuse large B-cell lymphoma, Keystone Symposia Conference, Victoria, British Columbia, Canada, 2010
- 45.-Greaves WO, Kim JE, Kunkalla K, Medeiros LJ, Singh R, **Vega F**. Glioma-associated oncogene homologue-3 (GLI3): A novel marker for classical Hodgkin lymphoma. *Mod Pathol* 23:289A, 2010
- 46.-Greaves WO, Kim JE, Kunkalla K, Medeiros LJ, Singh R, **Vega F**. Hedgehog signaling pathway is aberrantly activated in a subset of high grade lymphomas. *Mod Pathol* 23:298A, 2010

- 47.-Buglio D, Palakurti S, **Vega F**, Neelapu S, Berry D, Ji Y, Myth K, Younes A. Inhibition of Tak-1 by AZ-Tak1 impairs NF- κ B activation, downregulates XIAP and activates Caspase-9 inducing apoptosis in mantle cell lymphoma. *Blood* 116A:1175, 2010
- 48.-Sanchez-Espiridion B, Montalban C, Guisado P, Rodriguez ME, Canales M, Alves J, **Vega F**, Morente M, Tomás JF, Piris MA Garcia JF. microRNA expression signatures as prognostic markers in advanced classical Hodgkin lymphoma. *Blood* 116A:1692, 2010.
- 49.-Singh R, Kunkalla K, Greaves W, **Vega F**. Stroma-induced increase in ABCG2 Expression is involved in resistance to chemotherapy in diffuse large B-cell lymphoma. *Blood* 116A:428, 2010
- 50.-Garcia F, Sanchez-Espiridion B, Rodriguez ME, Canales M, Alves FJ, **Vega F**, Morente MM, Tomas JF, Montalban C, Guisado PM, Piris MA. miRNA expression signatures with prognostic significance in advanced classical Hodgkin lymphoma, European Association for Hematopathology, Upsala, Sweden, 2010
- 51.-Greaves WO, Sanchez-Espiridion B, Kunkalla K, Dave KS, Liang CS, Drakos E, Xiao L, Medeiros LJ, **Vega F**. Expression of the ATP-Binding Cassette Transporter MRP1 in Hodgkin/Reed-Sternberg Cells Is Associated with Lower Treatment Failure - Free Survival in Classical Hodgkin Lymphoma. *Lab Invest* 91:299A, 2011
- 52.-Sanchez-Espiridion B, Figueroa V, Montalban C, Guisado P, Rodriguez ME, Canales M, Alves FJ, **Vega F**, Younes A, Morente MM, Tomas JF, Piris MA, Garcia FJ. MicroRNAs in advanced classical Hodgkin lymphoma: signatures with prognostic significance. 11th International Meeting of Malignant Lymphomas, Lugano, Switzerland, 6/2011
- 53.-Qu C, Liu Y, Kunkalla K, Agarwal NK, Bourbon E, Pham KV, Ford RJ, Singh R **Vega F**. Smoothed (SMO), a G-protein-coupled receptor (GPCR) activated by Hedgehog Ligands, modulates the activity levels of PI3K/AKT and NF- κ B in Diffuse Large B-Cell Lymphoma. *Blood* 118A;1062, 2011. (abstract achievement award)
- 54.-Kunkalla K, Qu C, Liu Y, Singh R, **Vega F**. The t(14;18)(q32;q21) confers resistance to apoptosis-induced by smoothed inhibitors in diffuse large B-cell lymphoma that can be overcome by functional inhibition of BCL2. *Blood* 118A:1486-7,2011
- 55.-Bourbon E, Qu C, Liu Y, Kunkalla K, Liang CS, Leventaki V, Martinez F, Singh R, Agarwal NK, **Vega F**. Diffuse large B-cell lymphoma cells promote paracrine NF- κ B

activation in stromal cells and monocytes that is mediated by the hedgehog receptor smoothed (SMO). Tumor Microenvironment Complexity, AACR, Orlando, FL. 2011

56.-Alayed K, Kunkalla K, Qu C, Chakhachiro Z, Medeiros LJ, Singh R, **Vega F**. Glioma-associated oncogene homologue 3, a hedgehog transcription factor, contributes to the classical Hodgkin lymphoma microenvironment through the modulation of a subset of inflammatory chemokines and cytokines. *Mod Pathol* 25; 321A, 2012

57.-Leventaki L, Bourbon E, Qu C, Liu Y, kunkalla K, Nguyen, Bueso-Ramos C, Singh R, Agarwal N, **Vega F**. Diffuse large B-cell lymphoma cells promote paracrine activation of NF- κ B pathway in tumor-associated stromal cells. *Mod Pathol* 25; 351A, 2012

58.-Leventaki L, Kunkalla K, Liu Y, Qu C, Agarwal N, Medeiros LJ, **Vega F**. Expression of Aldehyde dehydrogenase 1 (ALDH1) by tumor-infiltrating macrophages and dendritic cells in mature B cell lymphomas. Symposia on Cancer Research 2012: Immunology and Inflammation in Cancer. MD Anderson Cancer Center, Houston, 10/2012

59.-Qu C, Liu Y, Kunkalla K, Agarwal NK, **Vega F**. Smoothed activates NF- κ B pathway through PKC β /CARMA1/TRAF6 activation and TRAF6 stabilization in diffuse large B-cell lymphoma. *Blood* 120A,1298, 2012. (abstract achievement award)

60.-Agarwal NK, Qu C, Kunkalla K, Liu Y, **Vega F**. GLI1 Directly Regulates the Transcription of *AKT* Genes in Diffuse Large B-Cell Lymphoma. *Blood* 120A, 2399, 2012

61.-Qu C, Liu Y, Kunkalla K, Singh RR, Blonska M, Agarwal NK, Lin X, **Vega F**. Trimeric G protein-CARMA1 axis links smoothed to NF- κ B activation in diffuse large B-cell lymphoma. AACR Annual Meeting 2013 (Washington)

62.-Leventaki L, Kunkalla K, Liu Y, Qu C, Agarwal N, Medeiros LJ, **Vega F**. Aldehyde dehydrogenase 1 (ALDH1) is a novel marker for tumor-associated macrophages and dendritic cells in mature B-cell lymphomas. *Mod Pathol* 26; 341A, 2013

63.-Agarwal NK, Kunkalla K, Hawke DH, Liu Y, Qu C, **Vega F**. Transcriptional Regulation Of *GLI1*, Potential New Therapeutic Target For Diffuse Large B-Cell Lymphoma. *Blood* 122A:2513, 2013

64.-Agarwal NK, Kunkalla K, Hawke DH, Liu Y, Qu C, **Vega F**. The inhibitor of NF- κ B kinase, IKK β , regulates the stability of GLI1 transcription factor. AACR 2014; San Diego.

65.-Agarwal NK, Kunkalla K, Kin CH, **Vega F**. Smoothened, hedgehog transducer, contributes to activate NF-kB pathway in diffuse large B cell lymphoma through stabilization of the E3 ligase TRAF6. 15th Annual Zubrod Memorial Lecture and Cancer Research Poster Session, 2014

66.-Agarwal NK, Kunkalla K, Kin CH, **Vega F**. Smoothened, Hedgehog Transducer, Contributes to Activate NF-KB Pathway in Diffuse Large B Cell Lymphoma through Stabilization of TRAF6. 2014 ASH Meeting on Lymphoma Biology. Colorado Springs. August 2014

67.-Blieden C, Zhou X, Amini S, **Vega F**, Cho-Vega JH. Cutaneous plasmablastic plasma cell myeloma with MYC gene amplification after antilogous stem-cell transplantation. 51st Annual meeting of the American Society of Dermatopathology Chicago 2014

68.-Deutsch Yehuda E, Campuzano-Zuluaga G, Salzberg M, Gomez Arteaga A, Watts JM, Chapman-Fredricks JR, Ikpat OF, **Vega F**, Swords RT. Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice? ASH 2014; San Francisco

69.-Agarwal NK, Kunkalla K, Kin CH, Lossos I, **Vega F** . The Inhibitor of NF-KB Kinase, IKK β Regulates the Transcriptional Activity of GLI1 By Blocking Its Proteasomal Degradation ASH 2014; San Francisco

70.-Agarwal NK, Kunkalla K, Kin CH, **Vega F** The Inhibitor of NF-kB Kinase, IKK β , Regulates the Stability of the Hedgehog Transcription Factor GLI1. USCAP 2015, Boston

71.-Zhou X; Rosenblatt J; **Vega F**; Cho-Vega JH. Selection and Rapid Proliferation of an Aggressive Transformed Mycosis Fungoides Clone in a Patient with Classic Mycosis Fungoides and Invasive Ductal Carcinoma Treated with Cytotoxic Chemotherapy. 23rd World congress of Dermatology 2015, Vancouver, Canada

72.-Moul A, Teomete U, Ikpat F, Chapman J, **Vega F**. HHV8 positive multicentric Castleman disease in an HIV negative patient. 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. October 2015, Long Beach, California.

73.-Ruiz-Cordero R, Moul A, Ikpatt F, Chapman J, **Vega F**. Unusual Immunophenotypic variant of extracavitary/solid primary effusion lymphoma expressing IgM. 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. October 2015, Long Beach, California.

74.-Mackrides N, Maque-Acosta Y, Moul A, Campuzano-Zuluaga G, Natkunam Y, **Vega F**, Chapman J. EBV-Positive Follicular Lymphoma: Another Age-Related Lymphoma With Aggressive Clinical Features? USCAP 2016, Seattle

75.-Mackrides N, Maque-Acosta Y, Moul A, Campuzano-Zuluaga G, **Vega F**, Chapman J. CD20 Negative Nodular Lymphocyte Predominant Hodgkin Lymphoma. USCAP 2016, Seattle

76.-Tan Y, Moul E, Gupta A, White KJ, Fan YS, **Vega F**, Chapman J. HIV-Associated Diffuse Large B-Cell Lymphoma has a disproportionate rate of MYC / BCL6 double translocations. USCAP 2016, Seattle

77.-Moul A, Tan Y, Hijazi N, Sanchez S, Ikpatt OF, Chapman J, **Vega F**. Double-Hit Lymphomas with BCL6 / MYC Translocations are Clinicopathologically Different from Those with IgH-BCL2 / MYC and from Triple-Hit Lymphomas. USCAP 2016, Seattle

78.-Gajzer DC, Tjendra Y, Kunkalla K, Kim CH, Ikpatt OF, Chapman J, Sanchez S, Yang G, Kwon D, **Vega F**, Agarwal NK. Clinical and Biological Significance of GLI1 Expression in Diffuse Large B-Cell Lymphoma. USCAP 2016, Seattle

79.-Tjendra Y, Agarwal NK, Kunkalla K, Hwa KC, Gupta A, Chapman J, Torres A, Alderuccio J, Chen SX, Kwon D, **Vega F**. Significance of Expression of SMO in Diffuse Large B-Cell Lymphoma. USCAP 2016, Seattle

80.-Agarwal NK, Kim CH, Kunkalla K, Tang G, Tjendra Y, Liu Y, Qu C, **Vega F**. Smoothed (SMO) is an adaptor protein that recruits TRAF6 and phospholipase C gamma 2 (PLCg2) to enhance the activation of NF-kB signaling pathway. ASH 2015, Orlando, FL

81.-Azzam D, Henry Volmar C, Ali Hassan A, Perez A, Watts JM, Vargas F, Elias R, **Vega F**, Zelent A, Cogle C, Wahlestedt C, Swords RT. A patient-specific Ex vivo screening platform for personalized acute myeloid leukemia (AML) therapy. ASH 2015, Orlando, FL

82.-Fisher OG, Fernandez MP, **Vega F**, Dubovy SR. Intraocular extramedullary hematopoiesis: a clinicopathologic case series. Association for research in vision and ophthalmology. 2016 Annual Meeting Research: A vision of hope, Seattle Washington.

83.- Monge J, Vaupel C, Swords RT, Bradley T, Chapman R, Gunaratne N, Chapman JR, **Vega F**, Padron E, Vargas F, Hall J, Watts J. Mutational frequency in Hispanics vs non-hispanic patients with acute myeloid leukemia. ASH 2016, San Diego, California

84.- Watts J, Perez A, Vargas F, Fan YS, Weismman A, Rodriguez A, Lopez O, **Vega F**, Swords RT, Zelent A. The Novel Translocation t(4;15)(q31;q22) in AML Is Associated with a Proliferative Phenotype in the Presence of All-Trans Retinoic Acid (ATRA). ASH 2016, San Diego, California.

21. Other Works Accepted for Publication:

V. PROFESSIONAL

22. Funded Research

Active

1-U01-CA-195568-01 (Lossos/Cerhan)	6/23/15 - 5/31/20
NIH-NCI	\$155,089
Lymphoma Epidemiology of Outcomes (LEO) cohort study.	
Role: Co- Principal Investigator	

Completed

S1400141 (Lossos)	8/1/14 - 7/31/16
SCCC	\$50,000
The Role of LMO2 in Double Strand DNA Repair and Lymphoma Pathogenesis	
Role: Co-Investigator	
M1501625 (Vega)	6/1/15 - 5/31/16

Women's Cancer Association	\$50,000
Effect of Combining SMO and BTK Inhibitors in a Human Diffuse Large B Cell Lymphoma Xenograft Model	
Role: Principal Investigator	

CTSI FY15Pilot Program Award (Vega)	6/1/2014 - 5/31/2015
Miami CTSI	
IKK β Regulates the Transcriptional Activity of GLI1 in Diffuse Large B-Cell	

Lymphoma. \$50,000
Role: PI

K08CA14315101 Physician-Scientist, K08 award. Role of Sonic Hedgehog Signaling in Diffuse Large B-Cell Lymphomas. Effort 75% (9 calendar months), NIH/NCI, 9/8/2010–8/31/2014, \$511,920
Role: Physician-Scientist

6235-11 (Vega) 10/1/2010–9/30/2014
Hedgehog Signaling a Therapeutic Target for Diffuse Large B-cell Lymphoma, Translational Research Program, Effort 1% (0.12 calendar months), Leukemia and Lymphoma Society, \$600,000
Role: PI

Cross-talking between Smoothed and NF-KB Signaling Pathway in Diffuse large B Cell Lymphoma, Effort 6% (0.7 calendar months), MD Anderson Institutional Research Fund Application, 7/2012–6/2014, \$50,000
Role: PI

Sonic Hedgehog Signaling Pathway as a Therapeutic Target in Diffuse Large B-cell Lymphoma, Effort 10% (1.2 calendar months), MD Anderson Institutional Research Fund Application, 7/2008–7/2010, \$50,000
Role: PI

Identification and Characterization of Tumor Initiating Cells in Chronic Lymphocytic Leukemia, Effort 10% (1.2 calendar months), 03-07-02531, CLL Global Research Foundation, 12/19/2007–12/28/2009, \$200,000
Role: PI

Hedgehog Signaling a Therapeutic Target for Diffuse Large B-Cell Lymphoma, Effort 1% (0.12 calendar), Developmental Research Award SPORE Lymphoma, 5/2010–5/2011, \$35,000
Role: PI

Role of Hedgehog Signaling in Diffuse Large B-Cell Lymphoma, Wendy Will Case Cancer Foundation, 2009, \$35,000
Role: Mentor of Dr. Rajesh Singh (Instructor, Department of Hematopathology at MDACC)

Targeting Sonic Hedgehog Signaling to Overcome Chemoresistance in Diffuse Large B-Cell Lymphoma, Effort 1% (0.12 calendar months), Lauri Strauss Leukemia Foundation, New York, 4/1/2010–3/31/2011, \$25,000.
Role: Co-PI and mentor of Dr. Rajesh Singh (Instructor, Department of Hematopathology),

Array-Based Comparative Genomic Hybridization (aCGH) in splenic and nodal marginal

zone lymphomas, MD Anderson Cancer Center Pathology Department Funds, 2005–2006, \$10,000

Role: PI and mentor of Vicky Leventaki (fellow, department of hematopathology at MDACC)

Protocols

Principal Investigator, Preclinical study sponsored by NIH CTEP in collaboration with Genentech to assess the utility of Hedgehog inhibitor GDC-0449 in diffuse large B-cell lymphomas. 2009, Pre-clinical trial, NIH/NCI, 2009.

Principal Investigator, Preclinical study with Genentech to assess the utility of Hedgehog inhibitor G025698 in diffuse large B-cell lymphoma, Pre-clinical trial, Genentech, 2009
Principal Investigator, Preclinical study with Genentech and Abbott Laboratories to assess the utility of the Hedgehog inhibitor G-025698 and the BCL-2 inhibitor ABT-737, in diffuse large B-cell lymphoma, Pre-clinical trial, Genentech and Abbott Labs, 2010.

Collaborator, Immunophenotypic and Molecular Characterization of HIV -Related Plasmablastic Lymphomas and Plasma Cell Myelomas/Plasmacytomas, LAB04-0457.

Collaborator, single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy (protocol Hx-CD20-405).

Collaborator, Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults with Relapsed or Refractory Hodgkin Lymphoma, 2010-0649, 2011–2013.

Collaborator, Phase 2 Multicenter, investigator initiated study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-cell Non-Hodgkin Lymphoma, 2011-0856, 2011-2013.

Collaborator, Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma, 2011-0805, 2011

Collaborator, Phase 2 Study of the HSP90 Inhibitor AUY922 in Patients with Relapsed and Refractory Lymphoma, 2011-0467, 2011

Collaborator, Phase 2 Study of Brentuximab Vedotin (SGN -35) in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma (NHL), 2011-0442, 2011

Collaborator, Phase III, multicenter, open-label, randomized trial comparing the efficacy of GA101 in combination with CHOP versus rituximab and CHOP in previously untreated patients with CD20-positive DLBCL. 2012-1155

Collaborator, SPI-ZV-11-301, phase III, open label, multicenter, randomized study of sequential zevalin (ibritumobab tiuxetan) versus observation in patients at least 60 years of age with newly Diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP-like therapy 2012-0504

Collaborator, A randomize, double bind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with DLBCL of RAD001 versus matching placebo after patients have achieved complete response with first line rituximab chemotherapy 2009-0973

Collaborator, Phase II study of BKM120 I patients with relapsed and refractory diffuse large B cell lymphoma, mantle cell lymphoma and follicular lymphoma.

23. Editorial Responsibilities

Editor/Service on Editorial Board(s)

Chief Editor, Internet Journal of Pathology, 2006–2008

Member of Editorial Review Board

Member Editorial Board of Human Pathology: Case Reports since 2016

Scientific Advisor of the Lymphoma Research Foundation (LFR) since 2016

Member Patient Publications Medical Review Committee of the Lymphoma Research Foundation (LRF) 2015

Editor Board Member, Annals of Diagnostic Pathology, 2012-present

Editor Board Member, International Journal of Clinical and Experimental Pathology, 2010–present

Associate Editor, American Journal of Blood Research, 2011-present

Journal Reviewer (since 2006 until present)

Patologia. Archives of Pathology & Laboratory Medicine, Journal of Cutaneous Pathology, Journal of Cellular and Molecular Medicine, Advances in Diagnostic Pathology, Cancer, Cancer Science, Haematologica, Internet Journal of Cancer, Lab Investigation, Leukemia Research, Modern Pathology, Advances in Anatomic Pathology, Blood, Cancer Research, Cleveland Clinic Journal of Medicine, Molecular Cancer Research, Pediatric Blood and Cancer, Yonsei Medical Journal, Histology and Histopathology, Neoplasia, Cancer Biomarkers, Diagnostic Pathology. Annals of Surgical Oncology.

Grant Reviewer

Grant Reviewer for Bloodwise (previously Leukemia Lymphoma Research) Clinical Research Training Fellowship. London, UK, 2016

Reviewer for the Mentoring and Career Development K12 award. CTSI University of Miami, 2015.

Reviewer for the Paracelsus Medical University (PMU) Research Fund (FFF) of the PMU Salzburg. Germany, 2014

Reviewer for NCI Special Emphasis Panel, Training and Career Development, 2013

Reviewer for the MDACC Institutional Grant Review Committee, MD Anderson, Member, 2009–2013

Reviewer for the Career Development Awards, NIH Scientific Review Group, 2012-2013

Grant reviewer for the Le Comité d'évaluation du programme Emergence 2012 from the French National Research Agency (ANR) (France), 2012

Reviewer for MDACC Sister Institution Network Foundation, Grant Reviewer, 2012

Grant reviewer for the chronic lymphocytic leukemia (CLL) Global Research Foundation, 2010

Grant reviewer for the Medical Research Council, London (UK), 2010

Other Review Activities

Reviewer of oral and poster abstracts, section of Non-Hodgkin Lymphoma: Biology, excluding Therapy. American Society of Hematology (ASH), 2015

Reviewer of the Hematopathology abstracts for the United States and Canadian Academy of Pathology (USCAP), 2012, 2013 and 2014.

Judge for the poster presentation of the Experimental Therapeutics Academic Program's student retreat, University of Texas, MD Anderson Cancer Center, 2012

24. Professional and Honorary Organizations:

Member, Spanish Society of Pathologists, Spain	1994–Present
Member, American & Canadian Academy of Pathology	1996–Present
Member, College of American Pathologists	2003–Present
Member, American Society of Hematology	2006–Present
Member, Society of Hematopathology/European Association for Haematopathology	2006-Present
Member, American Association for Cancer Research	2008–Present
Member, International Society of Stem Cell Research	2007–2010
Member, Texas Society of Pathologists, Houston, TX	2003–2013

25. Honors and Awards:

Scholarship from the Government of Navarra, Pamplona, Spain, 1996

"Manual Cabaleiro Goas" Award, Official School of Medical Doctors of Orense, Best Scientific Work 1998

Award for Best Platform Presentation, XX Meeting of the Galician Society of Gastroenterology, 1999

Postgraduate Grant from the Fundacion Pedro Barrie de la Maza La Coruna, Spain, 1999-2001

The Janice Davis Singletary Award for Clinical Fellowship in Lymphoma, MD Anderson Cancer Center, 2006

Mentor of Keith Newton, undergraduate student, awarded with the Annual Research Student Award of the Association of Genetic Technologists, 2008

Mentor of Raj Davuluri, pre-medical student, 1st Place of DeBakey Premedical School Research Award, Baylor College of Medicine, Houston, Texas, 2009

Mentor of Vicky Leventaki, fellow hematopathology, fellow research grant (funds from the Department of pathology at MDACC) "Immunophenotypic characterization of aldehyde dehydrogenase 1 (ALDH1) positive stromal dendritic cells in malignant lymphoma" 2012.

Mentor of Changju Qu, postdoctoral fellow in my laboratory, awarded with the Abstract achievement award, American Society of Hematology (ASH) meeting, San Diego, 2011.

Mentor of Changju Qu, postdoctoral fellow in my laboratory awarded with the Abstract achievement award, American Society of Hematology (ASH) meeting, Atlanta, 2012.

26. Other Professional Activities:

Organization of Conferences/Courses

Co-chair of the International Workshop of the Society of Hematopathology 2013. Progress in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Acute Lymphoblastic leukemia: Classification and molecular Pathogenesis. Houston, October 24-26, 2013

2011 American Society of Clinical Pathology/WASPaLM XXVI World Congress, Co-director of the educational hematopathology course, Las Vegas, NV, Co-director, 10/2011

Course/session moderator

57th Annual Meeting of the American Society of Hematology (ASH), Moderator of the Oral Session entitled "Non-Hodgkin's Lymphoma-Biology, excluding therapy: Clinical implications of genomic studies of B cell lymphoma, Moderator, 12/2015

Moderator of the Hematopathology session in the United States and Canadian Academy of Pathology (USCAP). Baltimore, 2013

Chair of the session “Myeloid neoplasms with PDGFR-A, -B and FGFR1 abnormalities. International Workshop of the Society of Hematopathology 2013. Progress in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Acute Lymphoblastic leukemia: Classification and molecular Pathogenesis. Houston, October 24-26, 2013

Co-director and speaker, Molecular Genetics/immunophenotype in new entities of the 2008 WHO Classification of Hematopoietic Neoplasms. American Society of Clinical Pathology Annual Meeting, Las Vegas NV, 10/2011

51st Annual Meeting of the American Society of Hematology (ASH), Moderator of the Oral Session entitled "Non-Hodgkin's Lymphoma-Biology, excluding therapy: Diffuse large B-cell lymphoma: Biology and Prognosis, Moderator, 12/2009

Invited Presentations Courses and from Other Institutions

Role of SMO in the biology of diffuse large B cell lymphoma. Fox Chase Cancer Center, Philadelphia 11/2016

Role of SMO in the biology of diffuse large B cell lymphoma. 18th meeting of the European Association for Haematopathology, Basel, Switzerland, 9/2016

Cross Talk between Hedgehog and NF-kB Pathways: A Novel Finding in the Pathobiology of Diffuse Large B Cell Lymphoma with Potential Therapeutic Implications. Pathology Ground Rounds, Karolinska Institute (Stockholm, Sweden) 6/2016

Cross Talk between Hedgehog and NF-kB Pathways: A Novel Finding in the Pathobiology of Diffuse Large B Cell Lymphoma with Potential Therapeutic Implications. LVII National Congress of the Spanish Society of Hematology (SEHH) and XXXI National Congress of the Spanish Society of Thrombosis and Hemostasis. Valencia (Spain). 10/2015

Understanding the biology lymphoma aid patient management? Science of lymphoma and associated receptors. Memorial Regional Hospital, Hollywood, FL, 9/2015

Role of Hedgehog signaling in the pathobiology of diffuse large B-cell lymphoma. Department of Pathology, Memorial Sloan Kettering, New York. 8/2015.

Role of Hedgehog signaling in the pathobiology of diffuse large B-cell lymphoma. Department of Pathology, Ann Arbor, University of Michigan. 5/2015.

Peripheral T cell lymphomas: A diagnostic approach. Advances in Diagnosis. 39th annual Review and Practical Advances in Pathology. Miami, FL. 2/2015

Understanding primary cutaneous T-cell lymphomas (non-mycosis fungoides). Santiago de Chile, Chile 10/2014.

Pathobiology of chronic lymphocytic leukemia/small lymphocytic lymphoma. Santiago de Chile, Chile 10/2014.

Diffuse large B cell lymphomas: Advances in Diagnosis. 38th annual Review and Practical Advances in Pathology. Miami, FL. 2/2014

Role of Hedgehog signaling in the biology of diffuse large B-cell lymphoma. Department of Pathology, University of Miami. 3/2013.

Role of Hedgehog signaling in the biology of diffuse large B-cell lymphoma. Department of Pathology, City of Hope, Duarte, California 2/2013.

Role of Hedgehog signaling in the biology of diffuse large B-cell lymphoma. Department of Pathology, University of North Carolina Chapel Hill, 8/2012.

Biomarkers detected by Immunohistochemistry in diffuse large B-cell lymphoma. Biomarker Driven Trial for Lymphoma Meeting. Chicago, 6/2012.

Understanding Cutaneous Lymphomas. Pathology Ground Rounds. Nebraska University, Omaha 5/2012.

Hedgehog signaling pathway: a potential therapeutic target for diffuse large B-cell lymphoma. Ground Rounds, Department of Pathology, University of Miami. 2/2012.

Understanding Cutaneous Lymphomas-Different Entities and Clinical Outcomes. 2012 Pan Pacific Lymphoma Conference. Lahaina, Maui, Hawaii, 7/2012.

Understanding Cutaneous Lymphomas-Different Entities and Clinical Outcomes. 2012 Neoplastic Hematopathology Update. Palm Beach, Florida, 11/2012.

Primary cutaneous Rosai-Dorfman Disease. 2012 Neoplastic Hematopathology Update. Palm Beach, Florida, 11/2012.

Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Ground Rounds, Seoul National University Cancer Center, Seoul, South Korea, 4/2011.

Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Surgical Pathology Update, Daegu, South Korea, 4/2011.

Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Asan Medical Center, Seoul, South Korea, 4/2011.

Lymphoma and Hematopoietic neoplasms involving skin, Surgical Pathology Update, Daegu, South Korea, 4/2011.

Hedgehog signaling in lymphomas, Pathology Ground Rounds, Cleveland Clinic, Cleveland, OH, 11/2010.

Cutaneous lymphoproliferative disorders. Course of Neoplastic Hematopathology Update: New Insights into Old Questions, Hollywood, FL, 11/2010

Speaker, Blastic plasmacytoid dendritic cell tumors. Neoplastic Hematopathology Update: New Insights into Old Questions, Hollywood, FL, 11/2010.

Diffuse large B-cell lymphoma, a diagnostic approach, The XII Annual Conference of Syrian Society of Pathology, Damascus, Syria, 4/2010.

New insights in the biology of diffuse large B-cell lymphoma, The XII Annual Conference of Syrian Society of Pathology, Damascus, Syria, 4/2010.

Diffuse large B-cell lymphoma in the 2008 WHO classification, Update course of Surgical Pathology, Sao Paulo, Brazil, 4/2009.

T-cell lymphomas in the 2008 WHO classification, Update course of Surgical Pathology, Sao Paulo, Brazil, 4/2009.

Aggressive B-cell lymphomas, Update Course of Surgical Pathology, Viña del Mar, Chile, 4/2008.

Anaplastic Large Cell Lymphoma, Update Course of Surgical Pathology, Viña del Mar, Chile, 4/2008.

Aggressive B-cell lymphomas, IV National Congress of Hematology and Oncology, Antigua, Guatemala, 8/2008.

Anaplastic large cell lymphomas, IV National Congress of Hematology and Oncology, Antigua, Guatemala, 8/2008.

Short Course: Bone Marrow Pathology, 3rd Intercontinental Congress of Pathology, Barcelona, Spain, 5/2008.

Anaplastic large cell lymphomas (ALK-positive and ALK negative), XXII Meeting of the Spanish Society of Pathology, Palma de Mallorca, Spain, 6/2006.

T- and NK-cell lymphomas, Workshop, Society of Hematopathology/European Association of Hematopathology, Houston, TX, 10/2005.

Aplicaciones de la patologia molecular en el estudio del cancer, Pasado, Presente y Futuro, Jornadas de Asma Y EPOC, Cristal-Pinor Hospital, Orense, Spain, 5/2004.

Celulas fibroblasticas del ganglio linfatico. Reunion Nacional del Club de Linfomas,

Hospital Juan Canalejo, La Coruna, Spain, 5/2004.

GeneScan and Real Time PCR, I Course of Molecular Pathology, Universidad de Navarra, Pamplona, Spain, 6/1/2002.

Probemática del diagnóstico y clasificación anatomopatológico de la Fibrosis Pulmonar Idiopática (FPI). Mesa Redonda en Neumopatías Intersticiales y de Origen Ocupacional, Hospital do Meixoeiro, Vigo, Spain, 5/1999.

Utilidad de la inmunohistoquímica y biología molecular en tejido linfóide necrótico, IX Course of Surgical Pathology, San Sebastian Hospital, San Sebastian, Spain, 10/1997.

Other Presentations at State and Local Conferences

Molecular Hematopathology I Medical Oncology Core Curriculum, University of Miami/Sylvester Cancer Center, Miami, 9, 2015

Molecular Hematopathology II Medical Oncology Core Curriculum, University of Miami/Sylvester Cancer Center, Miami, 9, 2015

Understanding primary cutaneous T-cell lymphomas (non-mycosis fungoides). Hematology/Internal Medicine Grand Rounds. University of Miami/Sylvester Cancer Center, Miami, 4, 2015

The inhibitor of NF- κ B kinase, IKK β , regulates the transcriptional activity of GLI1 by blocking its proteasomal degradation. Epigenetics and Cancer Colloquium Sylvester Comprehensive Cancer Center, Miami, FL, 8, 2014

Understanding the biology lymphoma aid patient management? Science of lymphoma and associated receptors. Miami, FL, 5/2014

IKK β stabilizes GLI1 and contributes to the activation of hedgehog signaling pathway. Retreat Meeting Sylvester Comprehensive Cancer Center, University of Miami, FL, 3/2014

Role of Hedgehog Signaling in Diffuse Large B-cell Lymphoma. Research Seminar, Hematopoietic malignancy group. Sylvester Cancer Center/University of Miami, FL, 2/2014

Role of Hedgehog Signaling in Diffuse Large B-cell Lymphoma. Research Seminar, MOET program meeting. University of Miami, FL, 1/2014

Role of SMO and GLI1 in diffuse large B cell lymphoma. Leukemia Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 6/2013

Diffuse large B-cell lymphoma, updates in new therapeutic approaches, Pathology Grand Rounds, University of Texas Medical Branch, Galveston, TX, 2012

Update in hedgehog signaling in diffuse large B-cell lymphoma, Leukemia Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 4/2012

Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Experimental Therapeutics Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2012

Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Cytogenetic Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 4/2011

Hedgehog signaling pathway: A new therapeutic approach for lymphomas, Leukemia Research Seminar, University of Texas, 9/2010

Role of sonic hedgehog signaling in lymphomas, Cytogenetic Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 3/19/2009

Role of sonic hedgehog signaling in lymphomas and leukemias, Leukemia Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 3/25/2009

Sonic hedgehog signaling is activated by NPM/ALK in ALK-positive anaplastic large cell lymphomas, MD Anderson Cancer Center, Houston, TX, 9/2008

Cancer Stem Cells, Pathology Ground Rounds, MD Anderson Cancer Center, Houston, TX, 3/2008

A molecular approach to monitoring disease progression in mycosis fungoides, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2001

A novel 4-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2001

VI. TEACHING

27. Teaching Awards Received:

Best teacher department of pathology, University Clinic of Navarra, years 1995-1997

28. Teaching Specialization:

Training Programs

Speaker, Principles in Neoplastic Hematology Lecture Series MD Anderson Cancer Center 2006–2008

Speaker, Cytogenetics Seminars, MD Anderson Cancer Center, 2006–2010

Speaker, Lymphoma Seminars, MD Anderson Cancer Center, 2006

Speaker, Current Topics in Human and Molecular Genetics Seminars, MD Anderson Cancer Center 2013.

29. Thesis and Dissertation Advising/Post-doctoral Student Supervision:

Since 2006- Direct supervision of undergraduate, graduate and medical students; postdoctoral fellows, research scientist, instructors and technicians in my research laboratory.

Undergraduate students: 10 (Keith Newton, Yogesh Davuluri, Christine Cain, Elsa Ramirez, Noelia Baez Rivera, Cynthia Liang, Kunal S Dave, Estelle Bourbon, Gloria Yang, Alexa Constantakos)

Medical Student: 1 (Yogesh Davuluri)

Graduate students: 2 (Beatriz Sanchez-Espiridon, Changju Qu)

Postdoctoral fellows: 7 (Rajesh Singh, Changju Qu, Chae H Kim, Christine Militto, Ji Eun Kim, Kim Chae Hwa, Youley Tjendra)

Research Scientist: 1 (Nitin Agarwal)

Instructor: 1 (Rajesh Singh)

Supervisor of clinical hematopathology fellows, MD Anderson Cancer Center 7/2006–8-2013 (4 to 6 fellows per year since 2006)

Supervisor of hematopathology fellows and Pathology residents, University of Miami, 9/2013-current (2 fellows per year; and 2 rotating pathology residents per month)

Supervisor of hematopathology visitors, University of Miami: 5 international visitors since 2013: Sandra Sanchez (Colombia), Jose Luis Solorzano (Spain), Hernan Quiceno (Spain), Ivan Gonzalez (Dominican Republic), Kumar Ganesh (India)

Teaching Outside of Current Institution

Previous Formal Teaching

Design of a web site with Pathologic Case presentations
www.cristalp.es/docencia/seccion1.htm, Complejo Hospitalario de Orense,
3/1998–3/1999

Teacher of practical and theoretical classes, anatomic pathology, University of Navarra (Pamplona Spain) 1994 – 1997.

Interactive Teaching of Pathology by Computer, Interpat Project, University Clinic of Navarra (Pamplona, Spain) 1994 – 1997.

VII. SERVICE

30. University Committee and Administrative Responsibilities:

Member of the Medical School Faculty Council. University of Miami, 2016-present

Member of the IRB committee of the University of Miami/Sylvester Comprehensive Cancer Center, 2015-present

Member of the Quality Assessment committee of the Department of Pathology, University of Miami, 2015-present

Member of the Research Committee of the Department of Pathology, University of Miami, 2015-present

Member of the Cancer Biology Graduate Program, University of Miami, 2014-present

Director of Division of Hematopathology
University of Miami/Sylvester Comprehensive Cancer Center
September 2013 – Present

Member of the Hematologic Malignancy Program, University of Miami/Sylvester Cancer Center, 2013-present

Member of the Leukemia/lymphoma faculty recruit committee, University of Miami/Sylvester Cancer Center, 2013-2014

Faculty, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, until 8/2013

Member of the Human and Molecular Genetics Program, 2012-8/2013 The University of Texas MD Anderson Cancer Center

Member of the Experimental Therapeutics Program, 2012-8/2013 The University of Texas MD Anderson Cancer Center

Lymphoma Section Head, Department of Hematopathology, Path/Lab Medicine
The University of Texas MD Anderson Cancer Center
January 2011 – August 2013

MD Anderson Cancer Center, Institutional Grant Review Committee (IRG), Member, 2009–2013.

MD Anderson Cancer Center, Institutional Large Cell Lymphoma Group, Member, 2011-2013.

MD Anderson Cancer Center, Institutional T-cell lymphoma Group, Member, 2011-2013.

MD Anderson Cancer Center, Institutional Hodgkin lymphoma Group, Member, 2011-2013.

MD Anderson Cancer Center, Institutional Credentialing Committee - Alternate Member, 8/2011-2013.

Member of advisory committee of graduate students, University of Texas, 2012-2013

Strike Force, Pathology Department, MD Anderson Cancer Center, Member, 2007–2009.

Medical and Surgical Academy of Orense (Spain), Member, 1/1998–11/1999.

Research Commission of Complejo Hospitalario de Orense (Spain), Member, 1/1998–11/1999.

Commission of Tissue and Mortality of Complejo Hospitalario de Orense (Spain), Member, 1/1998–11/1999.